1	Lipidomic profiling of human serum enables detection of pancreatic cancer
2	Denise Wolrab ¹ , Robert Jirásko ¹ , Eva Cífková ¹ , Marcus Höring ² , Ding Mei ^{3,4} , Michaela
3	Chocholoušková ¹ , Ondřej Peterka ¹ , Jakub Idkowiak ¹ , Tereza Hrnčiarová ¹ , Ladislav Kuchař ⁵ ,
4	Robert Ahrends ⁶ , Radana Brumarová ⁷ , David Friedecký ⁷ , Gabriel Vivo-Truyols ⁸ , Pavel
5	Škrha ⁹ , Jan Škrha ¹⁰ , Radek Kučera ¹¹ , Bohuslav Melichar ¹² , Gerhard Liebisch ² , Ralph
6	Burkhardt ² , Markus R. Wenk ^{3,4} , Amaury Cazenave-Gassiot ^{3,4} , Petr Karásek ¹³ , Ivo Novotný ¹³ ,
7	Roman Hrstka ¹⁴ , Michal Holčapek ^{1*}
8	¹ Department of Analytical Chemistry, Faculty of Chemical Technology, University of
9	Pardubice, Pardubice, Czech Republic.
10	² Institute of Clinical Chemistry and Laboratory Medicine, University Hospital of
11	Regensburg, Regensburg, Germany.
12	³ Singapore Lipidomics Incubator (SLING), Life Sciences Institute, National University of
13	Singapore, Singapore.
14	⁴ Department of Biochemistry, Yong Loo Lin School of Medicine, National University of
15	Singapore, Singapore.
16	⁵ Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First
17	Faculty of Medicine, Charles University and General University Hospital in Prague, Prague,
18	Czech Republic.
19	⁶ Department of Analytical Chemistry, University of Vienna, Vienna, Austria.
20	⁷ Palacký University Olomouc, Institute of Molecular and Translational Medicine, Olomouc,
21	Czech Republic.
22	⁸ Tecnometrix, Ciutadella De Menorca, Spain.
23	⁹ Third Faculty of Medicine, Charles University, Prague, Czech Republic.

- ¹⁰ 3rd Department of Internal Medicine, First Faculty of Medicine, Charles University, Czech
- 25 Republic.
- ¹¹ Department of Immunochemistry Diagnostics, University Hospital in Pilsen, Pilsen, Czech
- 27 Republic.
- 28 ¹² Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and
- 29 University Hospital, Olomouc, Czech Republic.
- 30 ¹³ Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech
- 31 Republic.
- 32 ¹⁴ Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute,
- 33 Brno, Czech Republic.
- 34 * Correspondence to: Michal.Holcapek@upce.cz

Pancreatic cancer has the worst prognosis among all cancers¹. Cancer screening 35 programs based on the analysis of body fluids can improve the survival time of patients, 36 who are often diagnosed too late at an incurable stage². Several studies have reported 37 the dysregulation of lipid metabolism in tumor cells and tissues³, suggesting that the 38 changes of blood lipidome may accompany tumor growth and progression. Analytical 39 methods based on mass spectrometry (MS) using either direct infusion or 40 chromatographic separation⁴ are convenient for high-throughput lipidomic profiling. 41 Here we show that the comprehensive quantitation of a wide range of serum lipids 42 43 reveals statistically significant differences between pancreatic cancer patients and 44 healthy controls visualized by multivariate data analysis. Initial results for 364 human serum samples in the discovery phase were subsequently verified in the qualification 45 phase on 554 samples measured by three independent laboratories, and finally on 830 46 47 samples from four blood collection sites in the verification phase. Concentrations suggestive of dysregulation of some very long chain sphingomyelins (SM 42:1, SM 41:1, 48 SM 39:1, and SM 40:1), ceramides (Cer 41:1, and Cer 42:1), 49 and (lyso)phosphatidylcholines (LPC 18:2) were recorded. Some lipid species indicated a 50 potential as biomarkers of survival. The sensitivity and specificity to diagnose pancreatic 51 cancer is over 90%, which outperforms CA 19-9, especially in early stage, and is 52 comparable to established imaging diagnostic methods. The accuracy of lipidomic 53 approach is not influenced by the cancer stage, analytical method, or blood collection 54 site. 55

Early cancer diagnosis based on non-invasive screening has been one of the major 56 unmet needs in medical research over the last decades¹. Some cancer types, such as pancreatic 57 cancer², do not show specific symptoms making the diagnosis at an early stage difficult. 58 Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of pancreatic cancers, is 59 mostly diagnosed at late stage resulting in the worst 5-year survival rate (7%) among all 60 61 cancers⁵. Imaging modalities used to diagnose PDAC in clinical practice included magnetic resonance imaging, computed tomography, endoscopic ultrasound, and positron emission 62 63 tomography, with accuracies reported in the meta-analysis of 5399 patients from 52 studies of 90%, 89%, 89%, and 84%, respectively⁶. Invasive procedures, *i.e.*, biopsies, were performed 64 65 only for the final confirmation of PDAC. Several types of blood tests were considered for PDAC screening⁷⁻⁹, such as carbohydrate antigen (CA) 19-9 measured alone or with other 66 blood proteins, e.g., carcinoembryonic antigen. The sensitivity and specificity of CA 19-9 67 68 were around 80% for advanced stages of PDAC, but dropped to 30-50% for small nonmetastatic tumors¹⁰, which prevents the utilization for early screening. *Kirsten-ras* (*KRAS*) 69 mutation testing currently used in the clinical practice for epithelial cancers (e.g., lung or 70 colorectal cancers) was considered for PDAC diagnostic using liquid biopsies, but the 71 sensitivity was too low. This mutation encountered in more than 90% of PDAC¹¹ and was 72 related to inferior overall survival. KRAS may be involved in the metabolic reprogramming of 73 fast proliferating tumor cell population towards elevated glucose and glutamine flows defined 74 as one of the hallmarks of cancer¹². Furthermore, the uptake of nutrients in KRAS mutated 75 cells can include blood lipids for the cell proliferation and survival^{13,14}. KRAS mutation has 76 been reported to be associated with the lipid metabolism in pancreatic cancer cells¹⁵. Lipids 77 have numerous functions in human metabolism¹⁶. Changes in the lipid metabolism were 78 already reported in other cancer types³, mostly for cell lines¹⁷, tissues¹⁸, but less frequently for 79 body fluids¹⁹. MS based lipidomic analysis has proven to be robust for high-throughput 80

- quantitation²⁰ and in combination with multivariate data analysis even small differences in
- 82 lipid profiles can be detected³.



83

Fig. 1. Overview of study design for the differentiation of PDAC patients (T, red) from 84 normal healthy controls (N, blue) and pancreatitis patients (Pan, green) based on the 85 lipidomic profiling of human serum using various mass spectrometry based approaches. 86 87 **a**, Phase I (discovery) for 364 samples (262 T + 102 N) divided into training (213 T + 79 N) and validation (49 T + 23 N) sets measured by UHPSFC/MS, shotgun MS (LR), and MALDI-88 MS. b, Phase II (qualification) for 554 samples (444 T + 98 N + 12 Pan) divided into training 89 90 (328 T + 82 N + 12 Pan) and validation (116 T + 16 N) sets measured by UHPSFC/MS, shotgun MS (LR and HR), and RP-UHPLC/MS at 3 different laboratories. c, Phase III 91 (verification) for 830 samples (546 T + 262 N + 22 Pan) divided into training (430 T + 246 N 92 93 + 22 Pan) and validation (116 T + 16 N) sets measured by UHPSFC/MS for samples obtained from 4 collection sites. 94

In the present study, we investigated the potential of comprehensive lipidomic profiling of human serum for PDAC detection. In most cases, the monitoring of single lipid species did not provide a reliable differentiation between cases and controls. Lipid species and

classes are interrelated, therefore a multi-analyte approach reflecting the whole lipidome 98 provides a stronger experimental design for clinical diagnostics. The overall methodologic 99 100 setup is described in Fig. 1 and in Methods. Exogenous lipid class internal standards (IS) were 101 added to serum before liquid-liquid extraction (Supplementary Table 1). Prepared extracts were analyzed by several MS approaches in individual study phases²¹ (Fig. 1). The analytical 102 103 validation of quantitative methods was performed in the Phase I in accordance with bioanalytical validation guidelines^{22,23} including two steps of guality control (details in 104 Methods)²⁴. Lipidomic MS data were processed using in-house script^{17,18}, and then 105 106 statistically evaluated by multivariate data analysis. The data set was split into training and 107 validation sets. The training set was used for building statistical models, which were then 108 applied for the prediction of samples from the validation set to verify the method performance for samples with unknown health status. The initial Phase I included 364 PDAC patients and 109 healthy control samples, which were analyzed by ultrahigh-performance supercritical fluid 110 $(UHPSFC)/MS^{24,25}$, chromatography shotgun MS, 111 and matrix-assisted laser desorption/ionization (MALDI)-MS²⁶. Small differences were observed in the lipidome 112 between males and females, therefore gender separated statistical models were further used in 113 114 this work (Extended Data Fig. 1). Subsequently, an extended cohort of 554 samples was analyzed in parallel by three independent laboratories and four different MS based approaches 115 (Phase II). Finally, 830 samples from four collection sites were analyzed by UHPSFC/MS 116 (Phase III). The method potential for diagnostic and prognosis purposes was evaluated with 117 118 advanced multivariate and univariate biostatistical tools. Molar concentrations (nmol/mL) of 119 all quantified lipid species (Supplementary Table 2) were used for all statistical analyses and 120 visualizations (Supplementary Tables 3 - 5). An overview of all human subjects and clinical information was provided in Supplementary Tables 6 and 7. 121

122 The statistical evaluation of UHPSFC/MS and shotgun MS data in the Phase I showed 123 a partial discrimination between cases and controls in principal component analysis (PCA)

124 score plots and distinct group differentiation when using supervised orthogonal projections to 125 latent structures discriminant analysis (OPLS-DA) models (Extended Data Fig. 1b,c and 126 2a,b). The predicted response values for training and validation sets obtained from OPLS-DA models based on the training set were used for building receiver operating characteristic 127 128 (ROC) curves. The area under the curve (AUC) values were over 0.99 for the training set and over 0.93 for the validation set (Extended Data Fig. 2c,d). Box plots for SM 41:1 illustrated 129 130 the same trend for both methods (Extended Data Fig. 2e,f). MALDI-MS, performed on a 131 limited number of 64 samples, provided complementary information about the down-132 regulation of some anionic glycosphingolipids, such as sulfatides (Extended Data Fig. 2g,h). 133 However, MALDI-MS measurements were not continued in the next phases, as the approach 134 is semi-quantitative.

The goal of the Phase II was to verify the results obtained in the Phase I by 135 independent laboratories. The extended cohort of 554 samples was measured by four different 136 MS based methods (UHPSFC/MS, shotgun MS with low-resolution (LR) and high-resolution 137 138 (HR), and RP-UHPLC/MS) with different lipidomic coverage (Extended Data Fig. 3). Results from Phases II and III were normalized to reported values of lipid species concentrations²⁷ in 139 the NIST reference material according to previously published work²⁸ (Supplementary Tables 140 4 and 5). ROC curves (Fig. 2a-d), OPLS-DA score plots, sensitivity, specificity, and accuracy 141 prepared separately for males (Extended Data Fig. 4a-h) and females (Extended Data Fig. 5a-142 h) indicated a clear discrimination of case and control groups for both training and validation 143 144 sets. Box plots constructed for the most significantly dysregulated lipid species (Fig. 2e-g, 145 Extended Data Fig. 4i, 5i, and 6) revealed a mutual comparability of molar concentrations 146 from individual laboratories, despite the use of different approaches for the sample 147 preparation and lipidomic quantitation. Based on the Phase II results, we hypothesize that outcomes should be reproducible for other laboratories experienced in the lipidomic analysis. 148 An important issue for PDAC screening is the differentiation between PDAC and chronic 149

pancreatitis patients (Extended Data Fig. 4i and 5i). Although, lipid profiles of chronic pancreatitis patients are comparable to healthy controls, the number of collected blood samples was not yet sufficient to draw significant conclusions, but this should be studied for a larger number of subjects within planned clinical validation.



155 Fig. 2. Comparison of Phase II results obtained at three different laboratories using four mass spectrometry based approaches. ROC curves for males (M) and females (F) in 156 training (Tr.) and validation (Va.) sets: a, UHPSFC/MS, b, shotgun MS (LR), c, shotgun MS 157 (HR), and **d**, RP-UHPLC/MS. Box plots of lipid concentrations normalized with the NIST 158 reference material for samples obtained from PDAC patients (443 T) and healthy controls (95 159 160 N) of both genders including both validation and training sets: e, SM 41:1, f, LPC 18:2, and g, Cer 41:1 for UHPSFC/MS (Method 1), shotgun MS (LR) (Method 2), shotgun MS (HR) 161 162 (Method 3), and RP-UHPLC/MS (Method 4).

In the Phase III, we investigated the method sensitivity for different blood collection sites, applicability for the early stage (T1 or T2) screening, effects of surgery, systemic therapy, and diabetes mellitus on lipidomic profiles. Statistical models for males (Fig. 3) and

females (Extended Data Fig. 7 and 8a) included 830 subjects from four collections sites, 166 167 before and during the treatment, before and after the surgery, without and with diabetes mellitus. PCA score plots indicated minor group differentiation (Fig. 3a and Extended Data 168 Fig. 7a), but OPLS-DA (Fig. 3b and Extended Data Fig. 7b) captured differences between 169 170 PDAC and controls, as illustrated by sensitivity, specificity, and accuracy values (Fig. 3c, 171 Extended Data Fig. 7c, and Supplementary Table 8). Lipid species with the highest influence on group clustering were selected based on S-plots (Fig. 3d and Extended Data Fig. 7d), box 172 173 plots (Extended Data Fig. 6), and statistical tests (Supplementary Table 9), and listed with 174 their fold changes, p-values, T-values, and variable influence of projection (VIP) values. Heat 175 maps were generated based on the most dysregulated lipids (Fig. 3e and Extended Data Fig. 176 7e).



Fig. 3. Results for the lipidomic profiling of male serum samples from PDAC patients
(T) and healthy controls (N) in the Phase III. a, PCA for the training set (219 T + 122 N).

180 **b**, OPLS-DA for the training set (219 T + 122 N). Individual samples are colored according to tumor (T) stage: T1 - yellow, T2 - orange, T3 - red, T4 - rose, and Tx - brown (no information 181 182 about the stage was provided). c, Sensitivity (red), specificity (blue), and accuracy (green) for 183 the training (219 T + 122 N) and validation (56 T + 6 N) sets. \mathbf{d} , S-plot for the training set 184 with the annotation of most up-regulated (red) and down-regulated (blue) lipid species. \mathbf{e}_{i} 185 Heat map for both training and validation sets (275 T + 128 N). f, OPLS-DA for early stages 186 T1+T2, age aligned (mean age is 65 ± 4 years for N and 67 ± 4 for T), and number aligned (39 T + 39 N). This graph includes both genders. 187

188 For PDAC screening, the key issue is the performance for early stage cancer detection, 189 because the clinical utility of such laboratory test for late stage is not likely. Unfortunately, early stage PDAC patients typically account for a small subgroup among all cases, but all 15 190 191 males and 23 females with T1 classification in our study are correctly assigned to cancer 192 group (Supplementary Table 10). We prepared OPLS-DA model solely for T1 and T2 tumors, 193 merging males and females into one set to reach a sufficient number of subjects for better 194 robustness and compared with age and number aligned healthy controls without any treatment 195 (Fig. 3f). This model supported the observation from other graphs that early stage patients were assigned with the same accuracy as for late phases (Extended Data Fig. 4a-d and 5a-d). 196 197 The prediction of health status in the validation set is based on predicted response values 198 calculated from OPLS-DA model in SIMCA software (Supplementary Table 10), where 199 values ≤ 0.5 are classified as normal, while values > 0.5 are predicted as PDAC (Extended Data 200 Fig. 7f). Regions >0.75 and <0.25 provide a very high level of confidence. On contrary, the 201 region 0.4 - 0.6 has the higher level of uncertainty, and the majority of false classifications 202 belongs to this middle region. The approach will be used for the future screening, when the 203 clinician will obtain positive/negative output with based on predicted response values together 204 with a single number from the interval <0-1> indicating the confidence of the prediction.

205 The most common chronic disease of pancreas is chronic pancreatitis, therefore 206 concentrations of the most dysregulated lipids SM 41:1 and Cer 41:1 were compared among 207 pancreatitis, PDAC, and healthy controls (Extended Data Fig. 8b,c). Lipid profiles of PDAC patients before and after surgery did not show any visible changes (Extended Data Fig. 8d-f), 208 209 which suggests that PDAC might be a systemic disease, and that tumor removal does not 210 cause immediate return of lipidomic profile to the premorbid condition. Medical treatment did 211 not affect lipid profiles of serum samples either (Extended Data Fig. 8g,h). Subjects with 212 diabetes mellitus were included in both case and control groups, and these cases do not 213 exhibit any measurable effect on the cluster discrimination, as illustrated by box plots for SM 214 41:1 as the most dysregulated lipid (Extended Data Fig. 8i). OPLS-DA models (Extended 215 Data Fig. 8j,k) were prepared for patients before any treatment and groups of age matched healthy controls to exclude any possible biases caused by treatment. The accuracy over 90% 216 217 and the same patterns of dysregulated lipids show that the actual treatment did not cause 218 relevant changes in lipid profiles.

219 From a biological point of view, the altered lipid metabolism may originate from 220 tumor cells, tumor stroma, apoptotic cells, and organs affected by PDAC metastatic spread. An immune response of the organism may also be involved. All these processes can naturally 221 222 contribute to the observed cancer lipidomic phenotype. In measurements from all involved laboratories, we observed a clear down-regulation of multiple lipid species in the serum of 223 224 PDAC patients (Extended Data Fig. 9), such as decreased levels of most very long chain 225 monounsaturated sphingomyelins and ceramides. These changes could be linked to the KRASdriven metabolic switch²⁹. In this context, alterations in sphingolipids concentrations deserve 226 227 attention, as the normal metabolism of sphingomyelins might be necessary to maintain KRAS function³⁰. Targeted biological investigations are needed to explain the mechanism of lipid 228 229 alterations in the serum of PDAC patients, but it will require the development of suitable animal models in the future. 230

231	Finally, we investigated the potential of lipids for prognostic purposes using Kaplan-
232	Meier plots, which enabled the visualization of individual parameters on the survival
233	prognosis from the lifetime data based on non-parametric statistics. The correlation of gender
234	(p=0.077) was not statistically significant (Extended Data Fig. 10a,b), but concentrations of
235	the following lipids exhibited a significant effect ($p < 0.05$) on the survival based on the data
236	from all participating laboratories (Fig. 4 a-c, Extended Data Fig. 10b-h, and Supplementary
237	Table 11). LPC18:2 was positively correlated with survival, which is in agreement with the
238	previous work ¹³ . In contrast, Cer 36:1, Cer 38:1, Cer 42:2, PC 32:0, PC O-38:5, and SM 42:2
239	were negatively correlated with the survival. CA 19-9 had a strong negative correlation with
240	the survival function (Extended Data Fig. 10i). Cox proportional-hazards model was another
241	regression tool used for the visualization of associations among survival time and predictor
242	variables (Fig. 4d), which demonstrated that the concentration of LPC 18:2 higher than
243	median was positively correlated with survival, while the opposite trend was observed for CA
244	19-9 and PC O-38:5.



Fig. 4. Potential of selected lipids for the survival prognosis in the Phase II measured by 246 **UHPSFC/MS**. Kaplan-Meier plots for: **a.** LPC 18:2 (n=128 for binary code 0, and n=72 for 247 binary code 1), **b**, Cer 36:1 (n=89 for 0, and n=111 for 1), and **c**, PC 32:0 (n=99 for 0, and 248 n=101 for 1). d, Cox proportional-hazards model for CA 19-9, PC 32:0, PC O-38:5, LPC 249 250 18:2; Cer 36:1, Cer 38:1, Cer 42:2, and SM 42:2. Lipid species concentrations normalized to 251 the NIST reference material obtained for all samples in the Phase II were converted into the binary code, whereby 0 was set for c < median and 1 for c > median (the median of 252 253 concentrations was calculated for each lipid species including all samples).

In summary, we developed a robust and high-throughput lipidomic profiling approach for early detection of PDAC in human serum, which is applicable for screening of at least 2,000 people per month on one MS system. The real clinical utility for early PDAC screening has to be confirmed in planned large prospective cohort for high-risk individuals (hereditary PDAC, newly diagnosed diabetes mellitus in patients over 50 years and with weight loss, and

patients with vague symptoms) including deeper investigation of other comorbidities. The
screening lipidomic test for PDAC will have a simple readout in the form of single number,
which provides a clear information on the health status for clinicians. All positive cases from
the lipidomic screening test must be confirmed by conventional diagnostic approaches.

263

264 METHODS

265 Chemicals and standards

266 In lab 1 (University of Pardubice, Czech Republic), solvents for sample preparation 267 and analysis, such as acetonitrile, 2-propanol, methanol (HPLC/MS grade), hexane, and 268 chloroform stabilized with 0.5-1 % ethanol (both HPLC grade), were purchased from either Sigma-Aldrich (St. Louis, MO, USA) or Merck (Darmstadt, Germany), respectively. Mobile 269 270 phase additives (ammonium acetate, ammonium formate, and acetic acid) were purchased from Sigma-Aldrich. Deionized water was obtained from a Milli-O Reference Water 271 272 Purification System (Molsheim, France). Carbon dioxide of 4.5 grade (99.995%) was 273 purchased from Messer Group (Bad Soden, Germany). Non-endogenous lipids used as 274 internal standards (IS) for the quantitative lipidomic analysis were purchased either from Avanti Polar Lipids (Alabaster, AL, USA), Nu-Chek (Elysian, MN, USA), or Merck. Lipid 275 276 concentrations used for the IS mixture are provided in the Supplementary Table 1 depending on the employed method, further details for the preparation and dilution of the IS mixture 277 278 used for UHPSFC/MS measurements were previously published¹. The NIST SRM 1950 279 metabolite reference plasma was used as quality control (QC) sample and for normalization of 280 concentrations between different MS based methods. Furthermore, a pooled serum sample of 281 PDAC patients and healthy controls were used as QC sample. The lipid annotation used in this manuscript²⁻⁴ is according to the recommendations of the Lipidomics standard initiative 282 283 (LSI) and given in Supplementary Table 2. The chemicals and standards mentioned above were used for the sample preparation and measurements performed in lab 1. 284

In lab 2 (University Hospital of Regensburg, Germany), chloroform and 2-propanol 285 286 were purchased from Roth (Karlsruhe, Germany) and methanol from Merck (Darmstadt, 287 Germany). All solvents were HPLC grade. Ammonium formate and cholesteryl ester (CE) standards were purchased from Sigma-Aldrich (Taufkirchen, Germany). TG and DG 288 289 standards were purchased from Larodan (Solna, Sweden) and dissolved in 2.2.4trimethylpenthane/2-propanol (3:1, v/v). Phosphatidylcholine (PC), ceramide (Cer), 290 291 sphingomyelin (SM), lysophosphatidylcholine (LPC), and lysophosphatidylethanolamine 292 (LPE) standards were purchased from Avanti Polar Lipids (Alabaster, Alabama, USA), and 293 dissolved in chloroform.

In lab 3 (National University of Singapore), chemicals and reagents were obtained
from the following sources: ammonium formate, acetic acid, and butanol from Sigma-Aldrich
or Merck (Darmstadt, Germany); MS-grade acetonitrile and methanol from Fisher Scientific
(Waltham, MA, USA); lipid standards from Avanti Polar Lipids (Alabaster, AL, USA).
Ultrapure water (18 MΩ·cm at 25°C) was obtained from an Elga Labwater system (Lane End,
UK).

300

301 Phases of the study

The study is categorized into three phases in line with the recommendation in the 302 literature⁵: Phase I (discovery), Phase II (qualification), and Phase III (verification). In Phase 303 304 I, 364 samples were investigated for the lipidomic serum profile differentiation of PDAC patients from healthy controls in the main laboratory (lab 1 - Pardubice) using UHPSFC/MS. 305 306 For the confirmation of results, the samples were again randomly processed and measured 307 with shotgun MS and, for a smaller subset, with MALDI-MS in lab 1. For Phase II, new 308 sample aliquots (554 samples) from the Masaryk Memorial Cancer Institute in Brno were 309 obtained, further re-aliquoted, and distributed among the laboratory at University of

310 Pardubice, Czech Republic (lab 1), laboratory at University Hospital of Regensburg, Germany 311 (lab 2), and laboratory at National University of Singapore (lab 3). Each laboratory processed 312 the sample set independently according to their preferred sample preparation method. For the quantitative lipidomic serum profile analysis in all three laboratories, no specifications of the 313 314 applied mass spectrometry-based method were provided. The purpose was that the individual laboratories should apply their preferred, optimized, and validated methods for the lipidomic 315 analysis. This experimental design is purposely selected to rule out that PDAC differentiation 316 317 from controls and dysregulation of specific lipids is method-or laboratory-dependent. The 318 following MS-based analytical methods were used for Phase II: UHPSFC/MS (lab 1), shotgun 319 MS with low- and high-resolution (lab 2), and RP-UHPLC/MS (lab 3). The sample 320 preparation protocol and lipidomic analysis was further developed and validated in the lab 1 between Phase I and Phase II, the optimized and validated conditions were applied for Phase 321 II and III^{1,6}. Phase III was performed in lab 1 using UHPSFC/MS for the serum lipidomic 322 323 analysis of samples obtained from different collection sites to verify that lipidomics profiling 324 is diagnostically conclusive and independent of the sample collection site. 554 samples from 325 Phase II are included in 830 samples of Phase III in lab 1.

326

327 Serum samples

Blood samples were drawn after overnight fasting. For Phase I (364 samples) and Phase II (554 samples), all human serum samples and clinical data were obtained from the Masaryk Memorial Cancer Institute in Brno, approved by the institutional ethical committees, and all blood donors signed informed consent. The sample selection was based on the availability of stored serum samples. The only exclusion criterion for healthy controls (normal, N) was the absence of malignant diseases in the life-time history without any other exclusion criteria for other diseases. For all PDAC patients, the disease was confirmed by

335 abdominal computed tomography and/or endoscopic ultrasound followed by needle biopsy or 336 surgical resection. All PDAC patients and healthy controls were of Caucasian ethnicity. The 337 samples were collected from 2013 to 2015. For Phase III (830 samples), serum samples and clinical data were provided by the Masaryk Memorial Cancer Institute in Brno (554 samples, 338 339 see Phase II), by the First and Third Faculty of Medicine at the Charles University in Prague (147 samples), by the University Hospital in Pilsen (31 samples) and by the Palacký 340 341 University and University Hospital in Olomouc (98 samples). 22 patients with chronic 342 pancreatitis (9 females and 13 males) treated at two outpatient departments were enrolled in 343 this study. The etiology of pancreatitis was either ethanol-induced or recurrent acute 344 pancreatitis. The diagnosis was confirmed by imaging methods (endoscopic ultrasound or 345 endoscopic retrograde cholangio-pancreatography). The overview and detailed description of clinical data and patient characteristics are provided in Supplementary Tables 6 and 7. The 346 347 samples were independently processed for each method used in the study. In order to avoid 348 biases due to the sample collection, sample preparation and measurements, all samples within 349 the particular phase were processed and measured in the randomized order. The operator had no information about the sample classification during the sample preparation and 350 351 measurements. The sample sets in all phases were divided into the training and validation sets to determine the assay performance using the rigid rule defined before the study that each 6^{th} 352 353 sample belongs to the validation set, and the rest constitutes the training set. The sample 354 classification for the training set was disclosed for the multivariate data analysis (MDA). The 355 classification of the validation set was disclosed after the final prediction of the validation set.

356

357 Sample preparation

Briefly, the whole blood was drawn into tubes containing no anticoagulant (Sarstedt S-Monovette, Germany) and incubated at room temperature for 60 min. Then, the samples were

360 centrifuged at $1500 \times \text{g}$ for 15 min, the serum was isolated, immediately frozen and stored 361 at -80°C until the extraction.

The final lipid extraction protocol in lab 1 represents a modified Folch procedure 362 published earlier^{1,7}. Human serum (25 μ L) and the mixture of IS (20 μ L) were homogenized 363 in 3 mL of chloroform/methanol (2:1, v/v) for 15 min in an ultrasonic bath (40°C). When 364 samples reached ambient temperature, 600 μ L of ammonium carbonate buffer (250 mM) was 365 added, and the mixture was ultrasonicated for 15 min. After 3 min of centrifugation (3000 366 367 rpm), the organic layer was removed, and 2 mL of chloroform was added to the aqueous 368 phase. After 15 min of ultrasonication and 3 min of centrifugation, the organic layers were 369 combined and evaporated under a gentle stream of nitrogen. The residue was dissolved in the 370 mixture of 500 μ L of chloroform/methanol (1:1, v/v) and vortexed. The sample preparation protocol in the Phase I was slightly different, because only single extraction was employed 371 372 without any buffer, with different IS concentrations, and only vortexing instead of ultrasonication. 373

Finally, the extract was diluted 1:5 with chloroform/methanol (1:1, v/v) or 1:20 with the mixture of hexane/2-propanol/chloroform (7:1.5:1.5, v/v/v) (Phase I) for the UHPSFC/MS analysis, 1:8 with chloroform/methanol/2-propanol (1:2:4, v/v/v) mixture containing 7.5 mM of ammonium acetate and 1% of acetic acid for the shotgun MS analysis, and 1:1 (v/v) with methanol for the MALDI-MS.

The lipid extraction in the lab 2 was performed according to the Bligh and Dyer protocol⁶ in the presence of exogenous lipid species as IS (Supplementary Table 1c) using 10 μ L of human serum for the extraction. Chloroform phase was recovered by the pipetting robot (Tecan Genesis RSP 150) and vacuum dried. Residues were dissolved in either 7.5 mM ammonium acetate in methanol/chloroform (3:1, v/v) (for low-resolution tandem mass spectrometry) or chloroform/methanol/2-propanol (1:2:4 v/v/v) with 7.5 mM ammonium formate (for high-resolution mass spectrometry).

386 The lipid extraction in the lab 3 was performed in a randomized order using the 387 stratified randomization based on the sample group, age, gender, and BMI. The sample 388 extraction was done over three days (~230 samples / day). Human serum samples (~100 μ L each) were taken out of -80° C freezer into a biosafety cabinet and thawed on ice. 10 μ L of 389 390 each serum sample was transferred into 1.5 mL Eppendorf tubes. In addition, 5 μ L of each serum sample was pooled together, mixed, and then 10 μ L was aliquoted in 59 Eppendorf 391 392 tubes to constitute batch quality control (BQC) samples. Process blanks (PBLK1-4) were 393 prepared by aliquoting 10 μ L of water into 1.5 mL Eppendorf tubes for the extraction control. 394 10 µL of commercial human plasma was pipetted into 1.5 mL Eppendorf tubes as reference 395 samples (LTR1-4). 10 µL of NIST SRM 1950 plasma was pipetted into 1.5 mL Eppendorf 396 tubes as additional reference samples (NIST1-4). The extraction was done on all abovementioned samples as follows: Add 190 μ L of chilled butanol/methanol (1:1, v/v) containing 397 398 IS to the samples. Vortex each sample for 10 seconds and sonicate in ice water for 30 min. 399 Centrifuge at 14,000 relative centrifugal force for 10 min at 4°C to pellet insoluble. Transfer 400 140 μ L of supernatant into clean vials. Pool 30 μ L of lipid extract from each vial (only from samples, not including BQC, NIST and LTR), mix, and aliquot into 59 vials as technical 401 402 quality control (TQC) samples. The TQC extract was diluted with chilled butanol/methanol (1:1, v/v) to prepare 80%, 60%, 40% and 20% diluted TQC solution, which were used to 403 404 assess the instrument response linearity. The lipid extracts in LC/MS vials were kept in the -80°C freezer until LC/MS/MS analysis. On the day of analysis, LC/MS vials were taken out 405 406 of the freezer, thawed at room temperature for 30 min, sonicated in ice-cold water for 15 min, 407 and injected into LC/MS/MS.

408

409 Measurements of CA 19-9

410 CA19-9, a mucin corresponding to the sialylated Lewis (Le)^a blood group antigen, was
 411 quantitatively determined using the electro-chemoluminescence immunoassay Elecsys[®]

(Roche, Rotkreuz, Switzerland) according to manufacturer instructions. The CA19-9 test was
performed only for PDAC samples. The cut-off value for the CA 19-9 test is 37 U/mL,
therefore all values over 37 U/mL were classified as PDAC.

415

416 UHPSFC/ESI-MS conditions (lab 1)

417 UHPSFC/MS measurements were carried out on the Acquity Ultra Performance Convergence Chromatography (UPC^2) system coupled to the hybrid quadrupole-traveling 418 419 wave ion mobility time-of-flight mass spectrometer Synapt G2-Si from Waters by using the 420 commercial interface kit (Waters, Milford, MA, USA). The chromatographic settings were used with minor improvements from previously published methods^{1,8}. The main difference is 421 that the data were recorded in the continuum mode. The peptide leucine enkephalin was used 422 as the lock mass with the scan time of 0.1 s and the interval of 30 s. The lock mass was 423 scanned but not automatically applied. The noise reduction was performed on raw files using 424 the Waters compression tool, and then data was lock mass corrected as well as converted into 425 the centroid data using the exact mass measure tool from Waters. For the data pre-processing, 426 the MarkerLynx software from Waters was used. Further data processing was done by 427 LipidQuant software available on figshare (https://figshare.com/s/cc087785ca362af7118e). 428

429

430 Shotgun MS conditions (lab 1)

Shotgun experiments were performed on the quadrupole-linear ion trap mass spectrometer 6500 QTRAP (Sciex, Concord, ON, Canada) equipped with the ESI probe. Characteristic precursor ion (PI) and neutral loss (NL) scan events were used for the detection of individual lipid classes and previously reported MS settings applied⁹. For the data analysis, all observed ions in the positive-ion mode characterized by m/z values, type of scan, and ion

436	intensities were exported as .txt data file and further processed using the LipidQuant software
437	available on figshare (https://figshare.com/s/b28049603a4f361c818b).

438

439 MALDI-MS conditions (lab 1)

MALDI matrix 9-aminoacridine (Sigma-Aldrich, St. Louis, MO, USA) was dissolved 440 441 in methanol – water mixture (4:1, v/v) to the concentration of 5 mg/mL. Diluted lipid extracts of serum were mixed with matrix (1:1, v/v). The volume of 1 μ L of extract/matrix mixture 442 was deposited on the target plate using the dried droplet crystallization. A small aliquot of 443 444 chloroform was applied onto MALDI plate spots before the application of diluted 445 extract/matrix mixture to avoid the drop spreading. Mass spectra were measured on the high-446 resolution MALDI mass spectrometer LTQ Orbitrap XL (Thermo Fisher Scientific, Waltham, MA, USA) equipped with the nitrogen UV laser (337 nm, 60 Hz) with a beam diameter of 447 448 about 80 μ m \times 100 μ m. The LTQ Orbitrap instrument was operated in the negative-ion mode over a normal mass range m/z 400 - 2000 with the mass resolution 100,000 (full width at half-449 maximum definition at m/z 400). The zig-zag sample movement with 250 µm step size was 450 451 used during the data acquisition. The laser energy corresponds to 15% of maximum, and 2 452 microscans/scan with 2 laser shots per microscan at 36 different positions were accumulated for each measurement to achieve a reproducible signal. Each sample (spotted matrix and lipid 453 454 extract mixture) was spotted five times. The total acquisition time for one sample, including measurements of five consecutive spots, was 10 min. Each measurement was represented by 455 456 one average MALDI-MS spectrum with thousands of m/z values. The automatic peak assignment was subsequently performed, and m/z peaks were matched with deprotonated 457 458 molecules from a database created during the identification procedure using the LipidQuant 459 software available on figshare (https://figshare.com/s/cb071be45cd91a7c90e2). This peak 460 assignment resulted in the generation of the list of present m/z of studied lipids with the

461 average intensities over all spectra, which was used for the further IS or relative normalization462 and the statistical evaluation.

463

464 Shotgun MS conditions (lab 2)

The analysis of lipids was performed by the direct flow injection analysis (FIA) using 465 a triple quadrupole (QqQ) mass spectrometer (FIA-MS/MS) and a Fourier Transform (FT) 466 hybrid quadrupole – Orbitrap mass spectrometer (FIA-FTMS). FIA-MS/MS was performed in 467 the positive ion mode using the analytical setup and the strategy described previously^{10,11}. The 468 fragment ion of m/z 184 was used for phosphatidylcholines (PC), sphingomyelins (SM)¹¹, and 469 lysophosphatidylcholines $(LPC)^{12}$. The following neutral losses were applied for: 470 phosphatidylethanolamines (PE) - 141, phosphatidylserines (PS) - 185, phosphatidylglycerols 471 (PG) - 189, and phosphatidylinositols (PI) - 277 (ref.¹³). PE-based plasmalogens (PE-P) were 472 analyzed according to the principles described by Zemski-Berry¹⁴. Sphingosine based 473 474 ceramides (Cer) and hexosylceramides (HexCer) were analyzed using the fragment ion of m/z264 (ref.¹⁵).475

FIA-FTMS setup was described in details in previous work¹⁶. Triacylglycerols (TG), 476 diacylglycerols (DG), and cholesteryl esters (CE) were recorded in the positive ion mode in 477 m/z range 500 - 1000 for 1 min with a maximum injection time (IT) of 200 ms, an automated 478 gain control (AGC) of 1.10^6 , 3 microscans, and a target resolution of 140,000 (at 200 m/z). 479 The mass range of negative ion mode was split into two parts. LPC and 480 lysophosphatidylethanolamines (LPE) were analyzed in the range m/z 400 - 650. PC, PE, PS, 481 482 SM, and ceramides were measured in m/z range 520 - 960. Multiplexed acquisition (MSX) was used for $[M+NH_4]^+$ of free cholesterol (FC) (m/z 404.39) and D7-cholesterol (m/z 411.43) 483 using 0.5 min of the acquisition time with the normalized collision energy of 10 %, IT of 100 484 ms, AGC of 1.10^5 , the isolation window of 1 Da, and the target resolution of 140,000. Data 485

486 processing details were described in Höring *et al.* using the ALEX software^{16,17}, which 487 includes the peak assignment procedure and the intensity picking. The extracted data were 488 exported to Microsoft Excel 2010 and further processed by the self-programmed Macros 489 available on figshare (https://figshare.com/s/e336bdf3a52f04c2de1f).

Lipid species were annotated according to the shorthand notation of lipid structures derived from mass spectrometry². For QqQ glycerophospholipid species, the annotation was based on the assumption of even numbered carbon chains only. SM species annotation is based on the assumption that a sphingoid base with two hydroxyl groups is present.

494

495 **RP-UHPLC/MS/MS conditions (lab 3)**

496 The RP-UHPLC/MS/MS analysis was performed on the Agilent UHPLC 1290 liquid 497 chromatography system connected to the Agilent QqQ 6495A mass spectrometer. The Agilent 498 Eclipse Plus C18 column (100 mm \times 2.1 mm, 1.8 μ m) was used for the LC separation. The mobile phases A (30% acetonitrile – 20% isopropanol – 50% 10mM ammonium formate in 499 H₂O, v/v/v + 0.1% formic acid) and B (90% isopropanol - 9% acetonitrile - 1% 10mM 500 ammonium formate in H_2O , v/v/v + 0.1% formic acid) were used for both positive and 501 502 negative ionization. The following gradient was applied: 0 min 15% B, 2.5 min 50% B, 2.6 min 57% B, 9 min 70% B, 9.1 min 93% B, 11 min 96% B, 11.1 min 100% B, 11.9 min 100% 503 504 B, and 12.0 min 15% B, held for 3 min (total runtime of 15 min). The column temperature was maintained at 45°C. The flow rate was set to 0.4 mL/min and the sample injection 505 506 volume was 2 µL.

507 The spray voltage was set to 3.5 kV in the positive ionization mode and 3 kV in the 508 negative ionization mode. The nozzle voltage was set at 1 kV. The drying gas temperatures 509 were kept at 150°C. The sheath gas temperature was 250°C. The drying gas and sheath gas

flow rates were 14 L/min and 11 L/min, respectively. The nebulizer gas setting was 20 psi.
The iFunnel high- and low-pressure RF were 180 V and 160 V, respectively, in the positive ionization mode and 90 V and 60 V, respectively, in the negative ionization mode. The MRM list is provided in the Supplementary Table 12.

Quantitative data were extracted by using the Agilent MassHunter Quantitative 514 Analysis (QqQ) software. The data were manually curated to ensure that the software 515 516 integrated the right peaks. Peak areas of extracted ion chromatograms peaks for each MRM 517 transition were exported to Microsoft Excel. Peak areas were normalized to peak areas of IS 518 using an in-house R script. The data quality was assessed using the following criteria, MRM transitions kept for the analysis had to satisfy: coefficient of variations (CoV) measured across 519 the QC injections < 20%, linearity TQC dilution series Pearson $R^2 > 0.80$, signal in processed 520 blanks < 10% of the signal observed in the QC. Data are available at figshare: 521 https://figshare.com/s/1fd10f273b049b93fa24 522

523

524 Method validation and quality control (lab 1)

The UHPSFC/MS method was validated in line with FDA and EMA guidelines, as 525 previously published¹. Solvent blanks and QC samples were regularly measured after each 40 526 samples. For the QC samples, a pooled serum sample and the NIST SRM reference plasma 527 528 sample were extracted and aliquoted. Furthermore, a mixture of naturally occurring lipid 529 species were used as a system suitability standard. In order to assess the instrumental state, the instrument stability and the sample preparation quality, the signal response of selected 530 531 endogenous lipids and the IS in all samples were monitored during the whole sequence. The 532 signal responses of selected lipids were plotted against the number of measured samples, 533 which allows the visualization of outliers due to the sample preparation or instrumental 534 failures. Typically, a gradual signal drop is observed for the IS caused by contamination of the

mass spectrometer over time.⁶ Furthermore, PCA for the lipidomic profiles in all samples was
performed to review for outliers and the clustering of QC samples.

537

538 Statistical analysis

SIMCA software, version 13.0 (Umetrics, Umeå, Sweden) was used to perform the 539 540 unsupervised PCA with unclassified samples, and the supervised OPLS-DA with the known sample classification. Only scatter plots of the first and second components are presented in 541 542 PCA score plots. OPLS-DA separates samples into known classes and can be used for the 543 prediction. First, studied lipids were defined as variables, and samples were defined as 544 different observations and further classified, *i.e.*, for the health state, gender, and cancer stage. 545 Differences in lipid profiles between genders were observed in the Phase I (Extended Data Fig. 1), therefore data sets for males and females were handled separately. The data sets were 546 pre-treated by a logarithmic transformation, centering, scaling (unit variance (UV) or Pareto 547 548 (Par) scaling), and evaluation of outliers. Logarithmic transformation was applied for each lipid species. Centering relates relative changes of a lipid species to the average, where UV or 549 Pareto scaling compensates the concentration variance differences for lipid species. The 550 551 scaling was chosen with regard to improved separation of PDAC patient and control samples and reduced number of outliers without using class information employing PCA. Pareto 552 scaling was superior for UHPSFC/MS, MALDI-MS, low- and high-resolution shotgun MS 553 554 (lab 2) and RP-UHPLC/MS (lab 3) measurements, and UV scaling for shotgun MS 555 measurements in lab 1 during Phase I. For PCA and OPLS-DA, the number of components 556 was assessed by model fit and prediction ability. In the case of too few components, the 557 differentiation of classes (*i.e.*, health state) is insufficient, while in the case of too many components, the model may be overfitted, resulting in diminished prediction power. The 558 559 model fit was determined by the evaluation of R2, which describes the variation of variables

560 (lipid species) explained by the model. The prediction ability of the model is described by Q2 561 and is estimated using a cross-validation. Cross-validation was performed by dividing the data 562 set into 7 groups, omitting one group, building the model, and predicting the omitted group. This was repeated for each group, and the results of the prediction were summarized by the 563 variable O2. For building models, components were added as long as O2 was increasing with 564 the number of components. Finally, PCA plot was evaluated for outliers, errors in 565 566 measurements, clustering of QC samples as well as for the separation of sample types, *i.e.*, 567 PDAC patients vs. healthy controls. Afterwards, OPLS-DA was performed in order to 568 discriminate between PDAC patients and healthy controls. The number of predictive and 569 orthogonal components for all methods is provided in Supplementary Table 8b. A confidence 570 level on parameters of 95% was used for all models.

OPLS models were built for the training set for individual methods and validated by 571 the prediction of the validation set using predicted response values. The unpredicted original 572 573 value of Y is 0, if a human subject is without cancer, and 1 in case of PDAC (binary variable). 574 Predicted response value is continuous and computed using the last model component. Based on the predicted value of Y, the sample is classified as non-cancerous subject (if predicted Y 575 576 ≤ 0.5) or cancerous subject (if predicted Y>0.5). A summary of predicted response values obtained for the training and validation sets with the various methods at the different clinical 577 578 phases is provided in the Supplementary Table 10. Depending on the correctly identified 579 healthy and cancerous samples, the selectivity, specificity, and accuracy of the model for the 580 training and validation samples were determined (Supplementary Table 8a).

In order to evaluate lipids of statistical significance, a two-sided two sample T-test assuming unequal variances (Welch test) was performed for healthy and cancerous samples. P-values <0.05 were considered to indicate the statistical significance. The Bonferroni approach was applied to all p-values for the multiple testing correction. The summary statistics and average molar lipid concentrations for healthy and cancerous samples are

586 summarized in the Supplementary Tables 9a-c for all methods and study phases. Furthermore, the parameter of variable influence of projection (VIP) was evaluated for each statistical 587 OPLS-DA model using the SIMCA software. Finally, only lipid species with p-values <0.05, 588 VIP values >1, and fold changes $\geq 20\%$ for molar concentrations were considered as 589 statistically important and reported in Supplementary Tables 9a-c. For the visualization of 590 591 differences in lipid concentrations (up- and down-regulation) between cancer and control 592 samples, box plots were constructed in R free software environment (https://www.r-593 project.org) using ggplot2, ggpubr, and rstatix packages. In each boxplot, the median was presented by a horizontal line, box represented 1st and 3rd guartile values, and whiskers stood 594 595 for 1.5*IQR from the median. Each measurement was plotted as jittered point value. The 596 receiver operating characteristics (ROC) curves were generated by using the package AUC in 597 R.

For verification of the data processing, statistical analysis and results, data were crosschecked and independently reprocessed or evaluated by applying the online metabolomics platform MetaboAnalyst (ver. 4.0)¹⁸.

For the Kaplan-Meier survival analysis and the Cox Hazard proportional analysis, lipid concentrations were converted into the binary code. Therefore, the median concentration of the lipid species for all samples were calculated, and individual lipid species concentrations were classified to 0, when the concentration was smaller than the median concentration of all samples or 1, when the concentration was bigger than the median concentration of all samples. The Kaplan-Meier survival analysis plots and the Cox-Hazard proportional analysis plots were generated by using the packages survival and survminer in R software.

608

609 **Outlier inspection**

610	The QC system and the PCA analysis revealed outliers. In Phase I, sample No. 355					
611	was excluded from the UHPSFC/MS data set, and sample No. 210 for the shotgun MS data					
612	set, due to the sample preparation failure. The repetition of the sample preparation was not					
613	possible due to insufficient serum volume. In the Phase II, samples No. 246 and 500 were					
614	excluded from the low resolution shotgun MS data set, and samples No. 246 and 409 from the					
615	high resolution shotgun MS data set.					
616						
617	Data availability					
618	All data necessary to support the conclusions are available in the manuscript or					
619	supplementary information. Raw data, instructions for the software handling and the software					
620	are deposited at figshare.com:					
621	https://figshare.com/s/5ddbcbf1be4a1aec966f					
622	https://figshare.com/s/b28049603a4f361c818b					
623	https://figshare.com/s/40f1450376cdc8d69e9a					
624	https://figshare.com/s/cb071be45cd91a7c90e2					
625	https://figshare.com/s/1fd10f273b049b93fa24					
626	https://figshare.com/s/e336bdf3a52f04c2de1f					
627	https://figshare.com/s/cc087785ca362af7118e					
628						
629	References					
630	1. Hur, C. et al. Early pancreatic ductal adenocarcinoma survival is dependent on size					
631	positive implications for future targeted screening. Pancreas 45, 1062-1066 (2016).					
632	2. Ryan, D.P., Hong, T.S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med.					
633	371 , 1039-1049 (2014).					

634	3.	Wolrab, D. et al. Oncolipidomics: Mass Spectrometric Quantitation of Lipids in
635		Cancer Research. Trends Anal. Chem. 120, 115480 (2019).
636	4.	Holčapek, M., Liebisch & G., Ekroos, K. Lipidomic analysis. Anal. Chem. 90, 4249-
637		4257 (2018).
638	5.	Cancer treatment & survivorship facts & figures. American cancer society.
639		https://www.cancer.org/research/cancer-facts-statistics/survivor-facts-figures.html
640		(2016-2017).
641	6.	Toft, J. et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A
642		systematic review and meta-analysis of sensitivity, specificity and diagnostic
643		accuracy. Eur. J. Radiol. 92, 17-23 (2017).
644	7.	Duffy, M.J. et al. Tumor markers in pancreatic cancer: a European group on tumor
645		markers (EGTM) status report. Ann. Oncol. 21, 441-447 (2010).
646	8.	Root, A., Allen, P., Tempst, P. & Yu, K. Protein biomarkers for early detection of
647		pancreatic ductal adenocarcinoma: progress and challenges. Cancers 10, 67-78 (2018).
648	9.	Cohen, J.D. et al. Detection and localization of surgically resectable cancers with a
649		multi-analyte blood test. Science 359 , 926-930 (2018).
650	10.	Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis,
651		prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17,
652		153–168 (2020).
653	11.	Jones S., et al. Core signaling pathways in human pancreatic cancers revealed by
654		global genomic analyses. Science 321 , 1801–1806 (2008).
655	12.	Bryant, K., Mancias, J., Kimmelman, A. & Der, C. KRAS: feeding pancreatic cancer
656		proliferation. Trends Biochem. Sci. 39, 91-100 (2014).

657	13.	Kamphorst, J. et al. Hypoxic and Ras-transformed cells support growth by scavenging
658		unsaturated fatty acids from lysophospholipids. Proc. Natl. Acad. Sci. USA. 110,
659		8882-8887 (2013).
660	14.	Salloum, D. et al. Mutant ras elevates dependence on serum lipids and creates
661		a synthetic lethality for rapamycin. Mol. Cancer Ther. 13, 733-741 (2014).
662	15.	Rozeveld, C.N., Johnson, K.M., Zhang, L., Razidlo, G.L. KRAS Controls Pancreatic
663		Cancer Cell Lipid Metabolism and Invasive Potential through the Lipase HSL. Cancer
664		<i>Res.</i> 80 , 4932-4945 (2020).
665	16.	Wenk, M.R. Lipidomics: new tools and applications. Cell 143, 888-895 (2010).
666	17.	Cífková, E. et al. Correlation of lipidomic composition of cell lines and tissues of
667		breast cancer patients using hydrophilic interaction liquid chromatography -
668		electrospray ionization mass spectrometry and multivariate data analysis. Rapid
669		Commun. Mass Spectrom. 31, 253-263 (2017).
670	18.	Cífková, E. et al. Determination of lipidomic differences between human breast cancer
671		and surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data
672		analysis. Anal. Bioanal. Chem. 407, 991-1002 (2015).
673	19.	Bandu, R., Mok, H.J. & Kim, K.P. Phospholipids as cancer biomarkers: mass
674		spectrometry-based analysis. Mass Spectrom. Rev. 37, 107-138 (2018).
675	20.	Heiskanen, L.A., Suoniemi, M., Ta, H.X., Tarasov, K. & Ekroos, K. Long-term
676		performance and stability of molecular shotgun lipidomic analysis of human plasma
677		samples. Anal. Chem. 85, 8757-8763 (2013).
678	21.	Rifai, N., Gillette, M.A., Carr, S.A. Protein biomarker discovery and validation: the
679		long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971-983 (2006).

680	22.	Guideline on bioanalytical method validation. Committee for medicinal products for
681		human use (CHMP).
682		http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_d
683		etail.jsp?webContentId=WC500109686%26mid=WC0b01ac058009a3dc (First
684		published 2011, last updated 2015).
685	23.	Food and drug administration guidance for industry: bioanalytical method validation.
686		US Department of health and human services. Center for drug evaluation and research:
687		Rockville, MD.
688		https://www.fda.gov/ForIndustry/IndustryNoticesandGuidanceDocuments/default.htm
689		(2001).
690	24.	Wolrab, D. et al., Determination of one year stability of lipid plasma profile and
691		comparison of blood collection tubes using UHPSFC/MS and HILIC-UHPLC/MS.
692		Anal. Chim. Acta 1137, 74-84 (2020).
693	25.	Lísa, M. & Holčapek, M. High-throughput and comprehensive lipidomic analysis
694		using ultrahigh-performance supercritical fluid chromatography-mass spectrometry.
695		Anal. Chem. 87, 7187–7195 (2015).
696	26.	Jirásko, R. et al. MALDI Orbitrap mass spectrometry profiling of dysregulated
697		sulfoglycosphingolipids in renal cell carcinoma tissues. J. Amer. Mass Spectrom. Soc.
698		28 , 1562-1574 (2017).
699	27.	Burla, B. et al. MS-based lipidomics of human blood plasma: a community-initiated
700		position paper to develop accepted guidelines. J Lipid Res. 59, 2001-2017 (2018).
701	28.	Triebl, A. et al. Shared reference materials harmonize lipidomics across MS based
702		detection platforms and laboratories. J. Lipid Res. 61, 105e115 (2020).

703	29.	Daemen, A. et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas
704		into subtypes with distinct sensitivities to metabolic inhibitors. Proc. Natl. Acad. Sci.
705		<i>USA</i> 112 , E4410-E4417 (2015).
706	30.	van der Hoeven, D. et al. Sphingomyelin Metabolism Is a Regulator of K-Ras
707		Function. Mol Cell Biol. 38, e00373-17 (2018).

708

709 **References Methods**

- 1. Wolrab, D., Chocholoušková, M., Jirásko, R., Peterka, O. & Holčapek, M. Validation
- of lipidomic analysis of human plasma and serum by supercritical fluid

chromatography–mass spectrometry and hydrophilic interaction liquid

chromatography–mass spectrometry. *Analytical and Bioanalytical Chemistry* **412**,

714 2375-2388 (2020).

715 2. Liebisch, G., *et al.* Shorthand notation for lipid structures derived from mass

spectrometry. *Journal of Lipid Research* **54**, 1523-1530 (2013).

- Fahy, E., *et al.* Update of the LIPID MAPS comprehensive classification system for
 lipids. *Journal of Lipid Research* 50, S9-S14 (2009).
- Fahy, E., *et al.* A comprehensive classification system for lipids. *Journal of Lipid Research* 46, 839-862 (2005).
- 721 5. Rifai, N., Gillette, M.A., Carr, S.A. Protein biomarker discovery and validation: the
 722 long and uncertain path to clinical utility. *Nature Biotechnology* 24, 971-983 (2006).
- 6. Wolrab, D., *et al.* Determination of one year stability of lipid plasma profile and
- comparison of blood collection tubes using UHPSFC/MS and HILIC-UHPLC/MS.
- 725 *Analytica Chimica Acta* **1137**, 74-84 (2020).
- 726 7. Bligh, E.G. & Dyer, W.J. A Rapid method of total lipid extraction and purification.
- 727 *Canadian Journal of Biochemistry and Physiology* **37**, 911-917 (1959).

720 0. Elsu, M., Chikova, E., Khaikova, M., Overenkova, M. & Holeapek, M. Elpia

- analysis of biological samples: Comparison of liquid chromatography, supercritical
- fluid chromatography and direct infusion mass spectrometry methods. *Journal of*
- 731 *Chromatography A* **1525**, 96-108 (2017).
- 732 9. Cífková, E., *et al.* Lipidomic differentiation between human kidney tumors and
 733 surrounding normal tissues using HILIC-HPLC/ESI–MS and multivariate data
- analysis. Journal of Chromatography B **1000**, 14-21 (2015).
- 10. Liebisch, G., *et al.* High throughput quantification of cholesterol and cholesteryl ester
- by electrospray ionization tandem mass spectrometry (ESI-MS/MS). *Biochimica et*
- 737 Biophysica Acta (BBA) Molecular and Cell Biology of Lipids 1761, 121-128 (2006).
- 11. Liebisch, G., Lieser, B., Rathenberg, J., Drobnik, W. & Schmitz, G. High-throughput
- quantification of phosphatidylcholine and sphingomyelin by electrospray ionization
- tandem mass spectrometry coupled with isotope correction algorithm. *Biochimica et*
- 741 Biophysica Acta (BBA) Molecular and Cell Biology of Lipids 1686, 108-117 (2004).
- Liebisch, G., Drobnik, W., Lieser, B. & Schmitz, G. High-Throughput Quantification
 of Lysophosphatidylcholine by Electrospray Ionization Tandem Mass Spectrometry. *Clinical Chemistry* 48, 2217-2224 (2002).
- 745 13. Matyash, V., Liebisch, G., Kurzchalia, T.V., Shevchenko, A. & Schwudke, D. Lipid
- extraction by methyl-tert-butyl ether for high-throughput lipidomics. *Journal of Lipid Research* 49, 1137-1146 (2008).
- Berry, K.A.Z. & Murphy, R.C. Electrospray ionization tandem mass spectrometry of
 glycerophosphoethanolamine plasmalogen phospholipids. *Journal of the American Society for Mass Spectrometry* 15, 1499-1508 (2004).
- 15. Liebisch, G., *et al.* Quantitative measurement of different ceramide species from crude
- cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS/MS).
- 753 *Journal of Lipid Research* **40**, 1539-1546 (1999).

754	16.	Höring, M., Ejsing,	C.S., Hermansson, I	M. & Liebisch,	G. Quantification of
-----	-----	---------------------	---------------------	----------------	----------------------

- 755 Cholesterol and Cholesteryl Ester by Direct Flow Injection High-Resolution Fourier
- 756 Transform Mass Spectrometry Utilizing Species-Specific Response Factors.
- 757 *Analytical Chemistry* **91**, 3459-3466 (2019).
- 17. Husen, P., et al. Analysis of Lipid Experiments (ALEX): A Software Framework for
- Analysis of High-Resolution Shotgun Lipidomics Data. *PLOS ONE* **8**, e79736 (2013).
- 18. Chong, J. & Xia, J. MetaboAnalystR: an R package for flexible and reproducible

analysis of metabolomics data. *Bioinformatics* **34**, 4313-4314 (2018).

762

763 Acknowledgments

The project was funded by the project 18-12204S (the Czech Science Foundation). L.K. acknowledges the support of institutional program of the Charles University in Prague (UNCE 204064). R.H. acknowledges the support of MEYS – BBMRI-CZ LM2018125 (the Ministry of Education, Youth and Sports of the Czech Republic) and MH CZ - DRO (MMCI, 00209805, the Ministry of Health of the Czech Republic) projects.

769 Author contributions

770 M.H., D.W., R.J., and E.C. prepared the design of experiments. D.W., M. Ch., and O.P.

performed sample preparation. D.W. analyzed sample by UHPSFC/MS, E.C. by shotgun MS,

and R.J. by MALDI-MS. M. Hör., D.M., G.L., R.B., M.R.W., and A.C.G. performed analysis

and data evaluation in cooperating laboratories. E.C. developed the software for data

- evaluation. D.W., R.J., T.H., E.C., J.I., and G.V.T. processed data and performed statistical
- analysis. L.K., R.K., D.F., and R.A. discussed observed changes. R.H., P.K., I.N., P.S., J.S.,
- 776 R.K., and B.M. obtained and provided serum samples and corresponding data. M.H., D.W.,
- and R.J. prepared the first draft of manuscript. D.W., R.J., J.I., and R.K. prepared figures.

- 778 M.H. was responsible for funding and supervision of this study. All co-authors read and
- approved the manuscript.

780 **Competing interests**

781 M.H., E.C., R.J., and D.W. are listed as inventors on patent EP 3514545 related to this work.

782 Extended Data - Figures legends

783

Extended Data Fig. 1. Effect of gender separation on the quality of OPLS-DA models
used for the differentiation of human serum samples obtained from PDAC patients (T)
and healthy controls (N) for the training set using UHPSFC/MS in the Phase I. a, Both
genders. b, Males. c, Females. d, Specificity, sensitivity, and accuracy for individual models.

788

789 Extended Data Fig. 2. Results for the Phase I obtained in the lab 1. Individual samples are colored according to tumor (T) stage: T1 - yellow, T2 - orange, T3 - red, T4 - rose, and Tx -790 791 brown (no information about the stage was provided). a, OPLS-DA for males measured with shotgun MS for the training set (104 T + 30 N). **b**, OPLS-DA for females measured with 792 shotgun MS for the training set (157 T + 49 N). ROC curves for males (M) and females (F) in 793 794 training (Tr.) and validation (Va.) sets: c. UHPSFC/MS, and d. shotgun MS. Box plots for 795 molar concentration in human serum from PDAC patients (T) and healthy controls (N) for males (M) and females (F): e, SM 41:1 measured by UHPSFC/MS, f, SM 41:1 measured by 796 shotgun MS (LR), for both box plots for males (104 T and 30 N) and females (109 T and 49 797 N), g, SHexCer 41:1(OH) measured by MALDI-MS, and h, SHexCer 40:1(OH) measured by 798 799 MALDI-MS, for both box plots for males (15 T and 14 N) and females (18 T and 19 N)

800

Extended Data Fig. 3. Summary of quantified lipid species for particular lipid classes.
Method 1 – UHPSFC/MS measured by lab 1 (n=202), Method 2 – shotgun MS with lowresolution (LR) measured by lab 2 (n=232), Method 3 – shotgun MS with high-resolution
(HR) measured by lab 2 (n=183), and Method 4 – RP-UHPLC/MS measured by lab 3

806	(n=431). Annotation of lipid classes: CE - cholesteryl esters, Cer - ceramides, DG -
807	diacylglycerols, TG – triacylglycerols, PC – phosphatidylcholines, LPC –
808	lysophosphatidylcholines, PE - phosphatidylethanolamines, PI - phosphatidylinositols, and
809	SM – sphingomyelins.

810

Extended Data Fig. 4. Results for the lipidomic profiling of male serum samples from 811 PDAC patients and healthy controls in the Phase II. OPLS-DA for molar concentrations of 812 813 lipid species obtained for the training set: **a**, UHPSFC/MS (166 T + 33 N), **b**, shotgun MS 814 (LR) (165 T + 33 N), c, shotgun MS (HR) (164 T + 33 N), and d, RP-UHPLC/MS (166 T + 815 33 N). Individual samples are colored according to their tumor (T) stage: T1 - yellow, T2 - yellow816 orange, T_3 – red, T_4 – rose, T_x – brown (no information about the stage was provided). 817 Sensitivity (red), specificity (blue), and accuracy (green) values in percentage for the training (Tr.) and validation (Va.) sets: e, UHPSFC/MS, f, shotgun MS (LR), g, shotgun MS (HR), 818 and h, RP-UHPLC/MS. i, Box plots of molar lipid concentrations normalized with the NIST 819 820 reference material determined in PDAC patients (222 T), controls (39 N), and pancreatitis (9 821 Pan) patients including both validation and training sets for SM 41:1 using UHPSFC/MS (Method 1), shotgun MS (LR) (Method 2), shotgun MS (HR) (Method 3), and RP-822 823 UHPLC/MS (Method 4).

Extended Data Fig. 5. Results for the lipidomic profiling of female serum samples from
PDAC patients (T) and healthy controls (N) in the Phase II. OPLS-DA for molar
concentrations of lipid species obtained for the training set: a, UHPSFC/MS (161 T + 46 N),
b, shotgun MS (LR) (160 T + 46 N), c, shotgun MS (HR) (161 T + 46 N), and d, RPUHPLC/MS (161 T + 46 N). Individual samples are colored according to their tumor (T)
stage: T1 - yellow, T2 - orange, T3 - red, T4 - rose, and Tx - brown (no information about the

stage was provided). Sensitivity (red), specificity (blue), and accuracy (green) values in
percentage for the training and validation sets: e, UHPSFC/MS, f, shotgun MS (LR), g,
shotgun MS (HR), and h, RP-UHPLC/MS. i, Box plots of molar lipid concentrations
normalized with the NIST reference material determined in PDAC patients (221 T), controls
(56 N), and pancreatitis (3 Pan) patients including both validation and training sets for SM
41:1 using UHPSFC/MS (Method 1), shotgun MS (LR) (Method 2), shotgun MS (HR)
(Method 3), and RP-UHPLC/MS (Method 4).

838

Extended Data Fig. 6. Selected box plots for the Phase II. Lipid concentrations normalized
with the NIST reference material determined in PDAC patients (443 T) and healthy controls
(95 N) including both validation and training sets and both genders: a, PC O-34:2, b, PC O34:3, c, PC O-36:4, d, Cer 36:1, e, Cer 42:1, f, Cer 42:2, g, SM 39:1, h, SM 40:1, i, SM 42:1,
j, LPC 16:0, k, LPC 20:4, and l, TG 52:6 for UHPSFC/MS (Method 1), shotgun MS (LR)
(Method 2), shotgun MS (HR) (Method 3), and RP-UHPLC/MS (Method 4).

845

Extended Data Fig. 7. Results for the lipidomic profiling of female serum samples from 846 847 PDAC patients (T) and healthy controls (N) in the Phase III. a, PCA for the training set 848 (211 T + 124 N). **b**, OPLS-DA for the training set (211 T + 124 N). Individual samples are 849 colored according to their tumor (T) stage: T1 - yellow, T2 - orange, T3 - red, T4 - rose, and Tx - brown (no information about the stage was provided). c, Sensitivity (red), specificity 850 (blue), and accuracy (green) for the training and validation sets. **d**, S-plot for the training set 851 852 with the annotation of most up-regulated (red) and down-regulated (blue) lipid species. e, 853 Heat map for both training and validations sets (271 T + 134 N).

855 Extended Data Fig. 8. Results for the lipidomic profiling of human serum samples for 856 PDAC patients (T) and healthy controls (N) including both genders in the Phase III. a, 857 ROC curves for males (M) and females (F) in training (Tr.) and validation (Va.) sets. Box plots of lipid molar concentrations normalized using the NIST reference material for: **b**, SM 858 859 41:1, and **c**, Cer 41:1. Only samples with known tumor (T) stage classification were included, where early stages (T1 and T2, 24 males and 30 females) and late stages (T3 and T4, 174 860 861 males and 176 females) are summarized and compared to samples of healthy controls (128 862 males and 134 females) and pancreatitis patients (13 males and 9 females). Influence of 863 surgery on the lipidomic profile: **d**, OPLS-DA for females (211 T + 124 N) using the training 864 set with highlighted samples before (green, n=13) and after (orange, n=10) surgery. Box plots 865 of molar lipid concentrations for paired samples collected before and after surgery for both genders (2 males and 10 females): e, SM 41:1, and f, LPC 18:2. Box plots for paired samples 866 867 collected before (n=22) and after treatment (n=22 for collection 1, n=12 for collection 2, n=7868 for collection 3, n=4 for collection 4) for both genders using molar concentrations: g, SM 41:1, h, LPC 18:2, and i, Cer 41:1. OPLS-DA modes only for subjects before any treatment or 869 870 surgery separately for j, males (83 T + 122 N) and k, females (73 T + 124 N).

871

Extended Data Fig. 9. Network visualization of the most dysregulated lipid species in PDAC for data from Phase III. Graphs show lipidomic pathways with clustering into individual lipid classes for **a**, males, and **b**, females using the Cytoscape software (http://www.cytoscape.org). Circles represent detected lipid species, where the circle size expresses the significance according to p-value, while the color darkness defines the degree of up-/down-regulation (red/blue) according to the fold change. The most discriminating lipids are annotated.

880 Extended Data Fig. 10. Potential of selected dysregulated lipid species for the survival

- **prognosis in the Phase II using Kaplan-Meier plots. a**, Gender (102 males and 98 females).
- **b**, PC O-38:5 measured by UHPSFC/MS (n=98 for binary code 0, and n=102 for binary code
- 1). c, PC O-38:5 measured by shotgun MS (LR) (n=103 for 0, and n=97 for 1). d, PC O-38:5
- measured by shotgun MS (HR) (n=103 for 0, and n=97 for 1). e, PC O-38:5 measured by RP-
- 885 UHPLC/MS (n=98 for 0, and n=102 for 1). f, PC 32:0 measured by shotgun MS (LR) (n=94
- for 0, and n=106 for 1). g, PC 32:0 measured by shotgun MS (HR) (n=91 for 0, and n=109 for
- 1). h, PC 32:0 measured by RP-UHPLC/MS (n=90 for 0, and n=110 for 1). i, CA 19-9 (n=62
- 888 for 0, and n=138 for 1).





		Number	Ν	Т	[%]	
M+F	Ν	79	73	6	92.4	Specificity
	Т	213	6	207	97.2	Sensitivity
	All	292	6	6	95.9	Accuracy
М	Ν	30	30	0	100.0	Specificity
	Т	104	2	102	98.1	Sensitivity
	All	134	2	0	98.5	Accuracy
F	Ν	49	49	0	100.0	Specificity
	Т	109	2	107	98.2	Sensitivity
	All	158	2	0	98.7	Accuracy







1.

Ż.

3.

Method

4.















